Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma

Journal of Proteomics

Volumn 94, Issue , 2013, Pages 346-358

  Yau, Wen Yea ^a   Shih, Han Chun ^a   Tsai, Mong Hsun ^b   Sheu, Jin Chuan ^a   Chen, Chien Hung ^a   Chow, Lu Ping ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Autoantibody; Hepatitis B virus; Hepatocellular carcinoma; Heterogeneous nuclear ribonucleoprotein L; Serological proteome analysis; Tumor associated antigens

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AUTOANTIBODY; BIOLOGICAL MARKER; EPITOPE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CELL GROWTH; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPROTEOMICS; IMMUNOREACTIVITY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; SURVIVAL RATE; TUMOR VOLUME;

AFP; AUTOANTIBODY; HCC; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN L; HNRNP L; SEROLOGICAL PROTEOME ANALYSIS; SEROLOGICAL PROTEOME ANALYSIS.; SERPA; TAAS; TUMOR-ASSOCIATED ANTIGENS; Α-FETOPROTEIN;

ANTIBODIES, ANTINUCLEAR; CARCINOMA, HEPATOCELLULAR; CELL LINE; EPITOPES; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN L; HUMANS; LIVER NEOPLASMS; MALE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886625085     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.10.003     Document Type: Article

References (48)

1. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273. [e1].
2. Sung J.L. Hepatitis B, virus infection and its sequelae in Taiwan. Gastroenterol Jpn 1984, 19:363-366.
3. El-Serag H.B. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002, 35:S72-S78.
4. Ogunbiyi J.O. Hepatocellular carcinoma in the developing world. Semin Oncol 2001, 28:179-187.
5. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
6. Lee W.M. Hepatitis B, virus infection. N Engl J Med 1997, 337:1733-1745.
7. Amin J., Dore G.J., O'Connell D.L., Bartlett M., Tracey E., Kaldor J.M., et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol 2006, 45:197-203.
8. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
9. Bruix J., Sherman M. Practice guidelines committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
10. Poon D., Anderson B.O., Chen L.T., Tanaka K., Lau W.Y., Van Cutsem E., et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118.
11. Lee J.M., Yoon J.H., Kim K.W. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012, 39:399-409.
12. Bertino G., Ardiri A., Malaguarnera M., Malaguarnera G., Bertino N., Calvagno G.S. Hepatocellualar carcinoma serum markers. Semin Oncol 2012, 39:410-433.
13. Masuzaki R., Karp S.J., Omata M. New serum markers of hepatocellular carcinoma. Semin Oncol 2012, 39:434-439.
14. Daniele B., Bencivenga A., Megna A.S., Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004, 127:S108-S112.
15. Stefaniuk P., Cianciara J., Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010, 16:418-424.
16. Cui J.W., Li W.H., Wang J., Li A.L., Li H.Y., Wang H.X., et al. Proteomics-based identification of human acute leukemia antigens that induce humoral immune response. Mol Cell Proteomics 2005, 4:1718-1724.
17. Yamamoto A., Shimizu E., Ogura T., Sone S. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 1996, 69:283-289.
18. Le Naour F., Brichory F., Misek D.E., Brechot C., Hanash S.M., Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002, 1:197-203.
19. Anderson K.S., Sibani S., Wallstrom G., Qiu J., Mendoza E.A., Raphael J., et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011, 10:85-96.
20. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:328-340.
21. Morita T., Tachikawa N., Kumamaru T., Nukui A., Ikeda H., Suzuki K., et al. Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients. Eur Urol 2000, 37:79-84.
22. Goodell V., Salazar L.G., Urban N., Drescher C.W., Gray H., Swensen R.E., et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006, 24:762-768.
23. Disis M.L., Bernhard H., Gralow J.R., Hand S.L., Emery S.R., Calenoff E., et al. Immunity to the HER-2/neu oncogenic protein. Ciba Found Symp 1994, 187:198-207. [discussion-11].
24. Disis M.L., Grabstein K.H., Sleath P.R., Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999, 5:1289-1297.
25. Yamamoto A., Shimizu E., Takeuchi E., Houchi H., Doi H., Bando H., et al. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999, 56:129-133.
26. Covini G., Chan E.K., Nishioka M., Morshed S.A., Reed S.I., Tan E.M. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997, 25:75-80.
27. Disis M.L., Bernhard H., Jaffee E.M. Use of tumour-responsive T cells as cancer treatment. Lancet 2009, 373:673-683.
28. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490.
29. Li L., Chen S.H., Yu C.H., Li Y.M., Wang S.Q. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res 2008, 7:611-620.
30. Takashima M., Kuramitsu Y., Yokoyama Y., Iizuka N., Harada T., Fujimoto M., et al. Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics 2006, 6:3894-3900.
31. Hudson M.E., Pozdnyakova I., Haines K., Mor G., Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 2007, 104:17494-17499.
32. Dib H., Tamby M.C., Bussone G., Regent A., Berezne A., Lafine C., et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 2012, 39:1405-1414.
33. Trembleau S., Hoffmann M., Meyer B., Nell V., Radner H., Zauner W., et al. Immunodominant T-cell epitopes of hnRNP-A2 associated with disease activity in patients with rheumatoid arthritis. Eur J Immunol 2010, 40:1795-1808.
34. Schett G., Dumortier H., Hoefler E., Muller S., Steiner G. B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease. Ann Rheum Dis 2009, 68:729-735.
35. Creaney J., Dick I.M., Yeoman D., Wong S., Robinson B.W. Auto-antibodies to beta-F1-ATPase and vimentin in malignant mesothelioma. PLoS ONE 2011, 6:e26515.
36. Hui J., Stangl K., Lane W.S., Bindereif A. HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol 2003, 10:33-37.
37. Liu X., Mertz J.E. HnRNP L binds a cis-acting RNA sequence element that enables intron-dependent gene expression. Genes Dev 1995, 9:1766-1780.
38. Guang S., Felthauser A.M., Mertz J.E. Binding of hnRNP L to the pre-mRNA processing enhancer of the herpes simplex virus thymidine kinase gene enhances both polyadenylation and nucleocytoplasmic export of intronless mRNAs. Mol Cell Biol 2005, 25:6303-6313.
39. Hwang B., Lim J.H., Hahm B., Jang S.K., Lee S.W. hnRNP L is required for the translation mediated by HCV IRES. Biochem Biophys Res Commun 2009, 378:584-588.
40. Hahm B., Kim Y.K., Kim J.H., Kim T.Y., Jang S.K. Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. J Virol 1998, 72:8782-8788.
41. Hamilton B.J., Wang X.W., Collins J., Bloch D., Bergeron A., Henry B., et al. Separate cis-trans pathways post-transcriptionally regulate murine CD154 (CD40 ligand) expression: a novel function for CA repeats in the 3'-untranslated region. J Biol Chem 2008, 283:25606-25616.
42. Hui J., Reither G., Bindereif A. Novel functional role of CA repeats and hnRNP L in RNA stability. RNA 2003, 9:931-936.
43. Shih S.C., Claffey K.P. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 1999, 274:1359-1365.
44. Boukakis G., Patrinou-Georgoula M., Lekarakou M., Valavanis C., Guialis A. Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. BMC Cancer 2010, 10:434.
45. David C.J., Chen M., Assanah M., Canoll P., Manley J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
46. Rauch J., O'Neill E., Mack B., Matthias C., Munz M., Kolch W., et al. Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res 2010, 70:1679-1688.
47. Tauler J., Zudaire E., Liu H., Shih J., Mulshine J.L. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res 2010, 70:7137-7147.
48. Goehe R.W., Shultz J.C., Murudkar C., Usanovic S., Lamour N.F., Massey D.H., et al. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J Clin Invest 2010, 120:3923-3939.